{"id":"W3106767035","doi":"10.1186/s13063-020-04925-8","title":"Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial","year":2020,"lang":"en","type":"letter","venue":"Trials","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China; Hunan Provincial Innovation Foundation for Postgraduate; Central South University; National Science Foundation","keywords":"Ixekizumab; Medicine; ARDS; Randomized controlled trial; Clinical trial; Immune dysregulation; Internal medicine; Immunology; Immune system; Secukinumab; Arthritis; Lung","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004857263,0.0006473195,0.01374411,0.0002144261,0.0001243448,0.00002712164,0.0001431531,0.0002697161,0.00002176622],"category_scores_gemma":[0.2958032,0.0003278831,0.001143094,0.0001468966,0.0006169838,0.00003438871,0.0001220846,0.0003572522,1.115143e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001855688,"about_ca_system_score_gemma":0.001592595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001177314,"about_ca_topic_score_gemma":0.00001153931,"domain_scores_codex":[0.9912269,0.003077595,0.003515756,0.0008658328,0.000904494,0.000409476],"domain_scores_gemma":[0.8318408,0.164317,0.002597089,0.000454643,0.0005461054,0.0002444113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9694551,0.002583945,0.0001576907,0.004814058,0.009404629,0.00002737242,0.0004698668,6.718548e-7,0.000008901292,0.000003373817,0.0109867,0.00208768],"study_design_scores_gemma":[0.8730305,0.09424093,0.00009138639,0.0003457654,0.006442101,1.884922e-7,0.00001919167,0.00002893503,0.00001148497,0.0001400038,0.02542847,0.0002210203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.002537169,0.00002914595,0.0003646597,0.0688425,0.00008870714,0.9267488,0.001349245,0.00003180781,0.000007975353],"genre_scores_gemma":[0.01097859,0.00005060419,0.0005949605,0.01722791,0.001570953,0.9689282,0.000284327,0.00009100881,0.0002734396],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.2909459,"threshold_uncertainty_score":0.9999173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1489104014543439,"score_gpt":0.4906283782849847,"score_spread":0.3417179768306409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}